Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking

Yongliang Li, Paul W. Brandt-Rauf, Walter P. Carney, Donald Y. Tenney, Jean G. Ford

Research output: Contribution to journalArticle

Abstract

Anti-p53 antibodies were examined in the plasma of 112 lung cancer patients by ELISA in order to study the distributions in lung cancer patients and the determinants of these antibodies in relation to lung cancer. Twenty (17.9%) lung cancer patients were found to have anti-p53 antibodies. The distribution of the antibodies by histological type was 7/48 (14.6%) adenocarcinoma, 8/32 (25.0%) squamous cell carcinoma, 3/7 (42.9%) small cell lung cancer, 0/4 large cell carcinoma, 0/8 adenosquamous cell carcinoma and 2/13 (15.4%) other types. By ethnicity, 8/44 (18.2%) Caucasians, 4/20 (20.0%) Hispanics and 8/48 (16.7%) African-Americans were positive for anti-p53 antibodies, with no significant differences among the groups (p = 0.5137). The antibody positivity rates were higher in lung cancer patients 55 years or older (21.2 %) than in the patients under 55 years (7.4%). The positive rates of the antibodies were 14.3% in non-smokers, 16.7% in ex-smokers and 19.1% in current smokers, with heavy smokers (≥41 pack-years) having the highest positive rate (28.6%), but none of these differences were statistically significant (p>0.05). Seven controls who had anti-p53 antibodies were all ex- smokers or current smokers and some had occupational exposures. No anti-p53 antibodies were found in 41 non-smoking controls. These results suggest that the development of anti-p53 antibodies in pulmonary carcinogenesis and its association with smoking and other carcinogenic exposures deserve further study.

Original languageEnglish (US)
Pages (from-to)381-390
Number of pages10
JournalBiomarkers
Volume4
Issue number5
DOIs
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Histology
Anti-Idiotypic Antibodies
Lung Neoplasms
Smoking
Antibodies
Adenosquamous Carcinoma
Cells
Large Cell Carcinoma
Small Cell Lung Carcinoma
Occupational Exposure
Hispanic Americans
African Americans
Squamous Cell Carcinoma
Carcinogenesis
Adenocarcinoma
Enzyme-Linked Immunosorbent Assay
Lung
Plasmas

Keywords

  • Anti-p53 antibody
  • Ethnicity
  • Histological type
  • Lung cancer
  • Pack- year
  • Smoking

ASJC Scopus subject areas

  • Biotechnology
  • Toxicology

Cite this

Li, Y., Brandt-Rauf, P. W., Carney, W. P., Tenney, D. Y., & Ford, J. G. (1999). Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers, 4(5), 381-390. https://doi.org/10.1080/135475099230769

Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. / Li, Yongliang; Brandt-Rauf, Paul W.; Carney, Walter P.; Tenney, Donald Y.; Ford, Jean G.

In: Biomarkers, Vol. 4, No. 5, 09.1999, p. 381-390.

Research output: Contribution to journalArticle

Li, Y, Brandt-Rauf, PW, Carney, WP, Tenney, DY & Ford, JG 1999, 'Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking', Biomarkers, vol. 4, no. 5, pp. 381-390. https://doi.org/10.1080/135475099230769
Li, Yongliang ; Brandt-Rauf, Paul W. ; Carney, Walter P. ; Tenney, Donald Y. ; Ford, Jean G. / Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. In: Biomarkers. 1999 ; Vol. 4, No. 5. pp. 381-390.
@article{02acb39c650a46069f46e70aaacd2156,
title = "Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking",
abstract = "Anti-p53 antibodies were examined in the plasma of 112 lung cancer patients by ELISA in order to study the distributions in lung cancer patients and the determinants of these antibodies in relation to lung cancer. Twenty (17.9{\%}) lung cancer patients were found to have anti-p53 antibodies. The distribution of the antibodies by histological type was 7/48 (14.6{\%}) adenocarcinoma, 8/32 (25.0{\%}) squamous cell carcinoma, 3/7 (42.9{\%}) small cell lung cancer, 0/4 large cell carcinoma, 0/8 adenosquamous cell carcinoma and 2/13 (15.4{\%}) other types. By ethnicity, 8/44 (18.2{\%}) Caucasians, 4/20 (20.0{\%}) Hispanics and 8/48 (16.7{\%}) African-Americans were positive for anti-p53 antibodies, with no significant differences among the groups (p = 0.5137). The antibody positivity rates were higher in lung cancer patients 55 years or older (21.2 {\%}) than in the patients under 55 years (7.4{\%}). The positive rates of the antibodies were 14.3{\%} in non-smokers, 16.7{\%} in ex-smokers and 19.1{\%} in current smokers, with heavy smokers (≥41 pack-years) having the highest positive rate (28.6{\%}), but none of these differences were statistically significant (p>0.05). Seven controls who had anti-p53 antibodies were all ex- smokers or current smokers and some had occupational exposures. No anti-p53 antibodies were found in 41 non-smoking controls. These results suggest that the development of anti-p53 antibodies in pulmonary carcinogenesis and its association with smoking and other carcinogenic exposures deserve further study.",
keywords = "Anti-p53 antibody, Ethnicity, Histological type, Lung cancer, Pack- year, Smoking",
author = "Yongliang Li and Brandt-Rauf, {Paul W.} and Carney, {Walter P.} and Tenney, {Donald Y.} and Ford, {Jean G.}",
year = "1999",
month = "9",
doi = "10.1080/135475099230769",
language = "English (US)",
volume = "4",
pages = "381--390",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking

AU - Li, Yongliang

AU - Brandt-Rauf, Paul W.

AU - Carney, Walter P.

AU - Tenney, Donald Y.

AU - Ford, Jean G.

PY - 1999/9

Y1 - 1999/9

N2 - Anti-p53 antibodies were examined in the plasma of 112 lung cancer patients by ELISA in order to study the distributions in lung cancer patients and the determinants of these antibodies in relation to lung cancer. Twenty (17.9%) lung cancer patients were found to have anti-p53 antibodies. The distribution of the antibodies by histological type was 7/48 (14.6%) adenocarcinoma, 8/32 (25.0%) squamous cell carcinoma, 3/7 (42.9%) small cell lung cancer, 0/4 large cell carcinoma, 0/8 adenosquamous cell carcinoma and 2/13 (15.4%) other types. By ethnicity, 8/44 (18.2%) Caucasians, 4/20 (20.0%) Hispanics and 8/48 (16.7%) African-Americans were positive for anti-p53 antibodies, with no significant differences among the groups (p = 0.5137). The antibody positivity rates were higher in lung cancer patients 55 years or older (21.2 %) than in the patients under 55 years (7.4%). The positive rates of the antibodies were 14.3% in non-smokers, 16.7% in ex-smokers and 19.1% in current smokers, with heavy smokers (≥41 pack-years) having the highest positive rate (28.6%), but none of these differences were statistically significant (p>0.05). Seven controls who had anti-p53 antibodies were all ex- smokers or current smokers and some had occupational exposures. No anti-p53 antibodies were found in 41 non-smoking controls. These results suggest that the development of anti-p53 antibodies in pulmonary carcinogenesis and its association with smoking and other carcinogenic exposures deserve further study.

AB - Anti-p53 antibodies were examined in the plasma of 112 lung cancer patients by ELISA in order to study the distributions in lung cancer patients and the determinants of these antibodies in relation to lung cancer. Twenty (17.9%) lung cancer patients were found to have anti-p53 antibodies. The distribution of the antibodies by histological type was 7/48 (14.6%) adenocarcinoma, 8/32 (25.0%) squamous cell carcinoma, 3/7 (42.9%) small cell lung cancer, 0/4 large cell carcinoma, 0/8 adenosquamous cell carcinoma and 2/13 (15.4%) other types. By ethnicity, 8/44 (18.2%) Caucasians, 4/20 (20.0%) Hispanics and 8/48 (16.7%) African-Americans were positive for anti-p53 antibodies, with no significant differences among the groups (p = 0.5137). The antibody positivity rates were higher in lung cancer patients 55 years or older (21.2 %) than in the patients under 55 years (7.4%). The positive rates of the antibodies were 14.3% in non-smokers, 16.7% in ex-smokers and 19.1% in current smokers, with heavy smokers (≥41 pack-years) having the highest positive rate (28.6%), but none of these differences were statistically significant (p>0.05). Seven controls who had anti-p53 antibodies were all ex- smokers or current smokers and some had occupational exposures. No anti-p53 antibodies were found in 41 non-smoking controls. These results suggest that the development of anti-p53 antibodies in pulmonary carcinogenesis and its association with smoking and other carcinogenic exposures deserve further study.

KW - Anti-p53 antibody

KW - Ethnicity

KW - Histological type

KW - Lung cancer

KW - Pack- year

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=0032821190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032821190&partnerID=8YFLogxK

U2 - 10.1080/135475099230769

DO - 10.1080/135475099230769

M3 - Article

C2 - 23902358

AN - SCOPUS:0032821190

VL - 4

SP - 381

EP - 390

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 5

ER -